EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

Michael M Poon, Kym I Lorrain, Karin J Stebbins, Geraldine C Edu, Alexander R Broadhead, Ariana O Lorenzana, Bryanna E Paulson, Christopher S Baccei, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong und 2 weitere

Scientific Reports · 2024

DOI: 10.1038/s41598-024-61369-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Michael M Poon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Contineum Therapeutics, San Diego, CA, 92121, USA. mpoon@contineum-tx.com. Hauptthemen laut MEDLINE: Multiple Sclerosis, Receptors, Lysophosphatidic Acid, Remyelination. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic neurological disease characterized by inflammatory demyelination that disrupts neuronal transmission resulting in neurodegeneration progressive disability. While current treatments focus on immunosuppression to limit inflammation and further myelin loss, no approved therapies effectively promote remyelination to mitigate the progressive disability associated with chronic demyelination. Lysophosphatidic acid (LPA) is a pro-inflammatory lipid that is upregulated in MS patient plasma and cerebrospinal fluid (CSF). LPA activates the LPA1 receptor, resulting in elevated CNS cytokine and chemokine levels, infiltration of immune cells, and microglial/astrocyte activation. This results in a neuroinflammatory response leading to demyelination and suppressed remyelination. A medicinal chemistry effort identified PIPE-791, an oral, brain-penetrant, LPA1 antagonist. PIPE-791 was characterized in vitro and in vivo and was found to be a potent, selective LPA1 antagonist with slow receptor off-rate kinetics. In vitro, PIPE-791 induced OPC differentiation and promoted remyelination following a demyelinating insult. PIPE-791 further mitigated the macrophage-mediated inhibition of OPC differentiation and inhibited microglial and fibroblast activation. In vivo, the compound readily crossed the blood–brain barrier and blocked LPA1 in the CNS after oral dosing. Direct dosing of PIPE-791 in vivo increased oligodendrocyte number, and in the mouse experimental autoimmune encephalomyelitis (EAE) model of MS, we observed that PIPE-791 promoted myelination, reduced neuroinflammation, and restored visual evoked potential latencies (VEP). These findings support targeting LPA1 for remyelination and encourage development of PIPE-791 for treating MS patients with advantages not seen with current immunosuppressive disease modifying therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisReceptors, Lysophosphatidic AcidRemyelinationAnimalsHumansMiceNeuroinflammatory DiseasesOligodendrogliaBrainCell DifferentiationEncephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLMyelin SheathLysophospholipidsBlood-Brain Barrier

Substanzen

Receptors, Lysophosphatidic AcidLysophospholipids

Autor:innen und Institutionen

  • Contineum Therapeutics, San Diego, CA, 92121, USA. mpoon@contineum-tx.com.
  • Contineum Therapeutics, San Diego, CA, 92121, USA.

Zitieren

APA

Poon, M. M., Lorrain, K. I., Stebbins, K. J., Edu, G. C., Broadhead, A. R., Lorenzana, A. O., Paulson, B. E., Baccei, C. S., Roppe, J. R., Schrader, T. O., Valdez, L. J., Xiong, Y., Chen, A. C., & Lorrain, D. S. (2024). Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis. Scientific Reports. https://doi.org/10.1038/s41598-024-61369-9

Vancouver

Poon MM, Lorrain KI, Stebbins KJ, Edu GC, Broadhead AR, Lorenzana AO, et al. Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis. Scientific Reports. 2024. doi:10.1038/s41598-024-61369-9

BibTeX
@article{Poon2024,
  author = {Poon, Michael M and Lorrain, Kym I and Stebbins, Karin J and Edu, Geraldine C and Broadhead, Alexander R and Lorenzana, Ariana O and Paulson, Bryanna E and Baccei, Christopher S and Roppe, Jeffrey R and Schrader, Thomas O and Valdez, Lino J and Xiong, Yifeng and Chen, Austin C and Lorrain, Daniel S},
  title = {Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis},
  journal = {Scientific Reports},
  year = {2024},
  doi = {10.1038/s41598-024-61369-9}
}
Kostenlos starten →